文献速递儿童青少年精神会诊联络精神医学

妊娠期甾醇通路干扰与孤独症谱系障碍风险的关联

Sterol pathway disruption in pregnancy: a link to autism.
PubMed 文献 · Mol Psychiatry · 2026-04-16

调整混杂因素后,妊娠期暴露于至少一种SBIM与ASD风险增加1.47倍(95% CI 1.45–1.49)相关,每多联用一种SBIM风险增加1.33倍(95% CI 1.32–1.34),同时使用4种及以上时风险达2.33倍。队列中ASD诊断率为3.8%(234,971例),其中15.0%(35,152例)的母亲妊娠期曾被处方至少一种SBIM;孕妇SBIM使用率从2014年4.6%升至2023年16.8%。

要点

  • 妊娠期暴露于至少一种SBIM与子代ASD风险增加1.47倍相关(95% CI 1.45–1.49)。
  • 每多联用一种SBIM,ASD风险增加1.33倍(95% CI 1.32–1.34);4种及以上时达2.33倍。
  • 孕妇SBIM使用率从2014年4.6%上升至2023年16.8%,处方前需权衡风险。

核心结论

  • 妊娠期SBIM暴露与子代ASD风险增加相关,且存在剂量-反应关系,提示SBIM可能对发育中的胎儿有潜在危害。

研究设计与样本

  • 采用Cox比例风险模型评估妊娠期母亲处方阿立哌唑、阿托伐他汀、安非他酮、丁螺环酮、氟西汀、氟哌啶醇、美托洛尔、奈必洛尔、普伐他汀、普萘洛尔、瑞舒伐他汀、舍曲林、辛伐他汀和/或曲唑酮等15种SBIM与子代ASD发病的关系,并调整潜在混杂因素。

主要发现

  • 妊娠期暴露于至少一种SBIM与ASD风险增加1.47倍相关(95% CI 1.45–1.49)。
  • 每多联用一种SBIM,ASD风险增加1.33倍(95% CI 1.32–1.34);同时使用4种及以上SBIM时风险达2.33倍。
  • 孕妇SBIM使用率从2014年4.6%上升至2023年16.8%。

关键数值与推荐

  • 妊娠期暴露于至少一种SBIM:ASD风险比1.47(95% CI 1.45–1.49)。
  • 每增加一种SBIM联用:ASD风险比1.33(95% CI 1.32–1.34)。
  • 同时使用4种及以上SBIM:ASD风险比2.33。
  • ASD诊断率3.8%(234,971/6,135,213),ASD患儿母亲妊娠期SBIM暴露比例15.0%(35,152/234,971)。
  • 孕妇SBIM使用率:2014年4.6%,2023年16.8%。

临床怎么用

  • 妊娠期处方SBIM前应充分权衡对子代ASD的潜在风险,尤其避免不必要的多药联用。
  • 鉴于SBIM在美国年处方量超过4亿张,临床医生在妊娠期用药决策中需考虑本研究提示的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cholesterol is a vital molecule, especially during embryonic development. Disruption of the cholesterol biosynthetic pathway can arise from pathogenic genetic variants or exposure to prescription medications. We investigated the relationship between fifteen sterol biosynthesis inhibiting medications (SBIM) prescribed during pregnancy and the incidence of autism spectrum disorders (ASD) in the resulting offspring. Our study of the Epic Cosmos database queried linked child and maternal health records for births between 2014 and 2023 with follow-up to December 2025. The study included 6,135,213 children with linked maternal health records. We evaluated the incidence of ASD associated with maternal prescription of aripiprazole, atorvastatin, bupropion, buspirone, fluoxetine, haloperidol, metoprolol, nebivolol, pravastatin, propranolol, rosuvastatin, sertraline, simvastatin, and/or trazodone during pregnancy using Cox proportional hazard modeling. We found that exposure to at least one SBIM during pregnancy was associated with a 1.47-fold (95% CI 1.45-1.49) increased risk of an ASD after adjusting for potential confounders. For each additional SBIM co-prescribed, there was a 1.33 (95% CI 1.32-1.34) times increased risk of ASD, reaching 2.33-fold risk when 4 or more SBIMs were prescribed simultaneously. In the ten years of our cohort, we identified 234,971 (3.8%) children with an ASD diagnosis. Of the children with an ASD diagnosis, 35,152 (15.0%) of the mothers were prescribed at least one SBIM during pregnancy. Notably, in our dataset, utilization of SBIM medications by pregnant women increased from 4.6% in 2014 to16.8% in 2023. In conclusion, SBIMs may be potentially harmful to the developing fetus. Given that these drugs account for over 400 million prescriptions annually in the U.S. we recommend these findings be considered before prescribing SBIM medications during pregnancy.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Peeples ES, Anzalone AJ, Dai R, et al. Sterol pathway disruption in pregnancy: a link to autism. Mol Psychiatry. 2026. PMID: 41991716. doi:10.1038/s41380-026-03610-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。